Aging's Zombie Cells Have an Inflammatory Fuel Line. Mayo Just Found the Valve.

This is a different kind of post than most of what I have written here. If you have been following along, you have mostly gotten cardiology: LDL, blood pressure, plaque, the reasons a low-risk person can still end up with a stent. This one goes upstream of all of that, into raw aging biology, and I want to say plainly why.

The hallmarks of aging are the language I use to judge almost every health, wellness, and longevity claim I run into. It is the closest thing biology has to a unifying map of why we break down with age, and it is the lens behind everything I file under aging biology.

Calibrated Age is the system I am building on top of that map: which hallmarks an intervention plausibly touches, what evidence supports each link, and whether that evidence stops at a mechanism, a biomarker, a mouse, or a human outcome. A paper like this one matters because it changes the map itself. It shows that something sold as simply "anti-inflammatory" might really be touching senescence, mitochondrial metabolism, chromatin, and cell-to-cell signaling all at once.

Soon, my writing will begin including specific interventions where I bring in a hundred-plus studies and map those studies to the hallmarks of aging via proxies such as associated biomarkers, known pathways, and disease states. True longevity studies that analyze things at the intervention level do not exist, because of economic and time-constraint realities. So, to use existing evidence as it is available, we must use proxies. I will analyze mechanism strength and evidence quality, along with important side criteria such as bioavailability, dosage realities, conflict of interest, and safety data from a half-dozen sources.

The piece I am writing today is an evidence breakdown. To effectively study and map interventions to the framework that makes up aging biology, I must stay on top of the headline literature surrounding how these hallmarks actually function. So, literature reviews pertaining to landmark studies will land when I think they truly move the needle. This one is foundational, and it is primarily mechanistic, so read it as a look at the machinery rather than a list of things to do or items to consider adding or tossing from your own health and wellness routine.

This paper also lands in a corner of the map I already know. I found my way into aging biology through cancer, and one of the epigenetic markers that changed in a melanoma study I worked on sits at the same spot this Mayo paper lands on: lysine 27 of histone H3 (H3K27).⁷ Same residue, different chemistry, and I will come back to why that matters.

The Mayo connection is more literal. The study came out of the Kogod Center on Aging. I work in Mayo's emergency department and am finishing my PhD through the University of Minnesota bioinformatics and computational biology program, which is run jointly with Mayo Clinic. I am not part of the Passos lab and had nothing to do with this paper. I follow the work because its biology sits at the intersection of the clinical system I work in, the PhD program I am completing, and the epigenetic machinery I once studied. Now onto the paper.

The Bottom Line

Some of the cells in your body are too damaged to keep dividing, but they refuse to die. They sit in your tissues and leak a steady stream of signals. Biologists call them senescent cells, and the leak has a name: the SASP. That leak is one important source of the low-grade, body-wide inflammation that climbs with age, the kind now tied to heart disease, frailty, dementia, and cancer.

For years the leading idea for dealing with these cells has been to kill them. A new Mayo-led study, published in Nature, takes a different route. It maps the supply chain that lets a senescent cell shout, and finds that you can cut the line without killing the cell. Damaged mitochondria in these cells run a metabolic pathway that ends in a molecule called acetyl-CoA, which the cell uses to keep the inflammation genes open enough to be read at full volume. Block one valve on that pathway, a transporter called SLC25A1, and the shouting quiets down while the cell stays put.

My read: the value here is not a new pill. It is one of the cleanest demonstrations I have seen of several hallmarks of aging working as one circuit rather than a checklist. Inside a single senescent cell, failing mitochondria, rewired metabolism, and an epigenetic switch converge to produce chronic inflammation, and the SASP then carries that signal out into the tissue. The study identifies one metabolic checkpoint inside that circuit. It does not show that every kind of age-related inflammation runs through this pathway, and it does not make a blood marker like CRP useless. It shows why a downstream number cannot tell you which upstream machinery actually changed.

Vocabulary that matters

• Senescent ("zombie") cell: a cell locked into durable growth arrest by damage, stress, or a biological program. It stays metabolically active and can alter the tissue around it through what it secretes.
• SASP (senescence-associated secretory phenotype): the mixture of cytokines, chemokines, growth factors, proteases, and other signals a senescent cell releases. The inflammatory part is the focus of this paper. In plain terms, it is the signal leaking out of the cell.
• Inflammaging: chronic, low-grade, whole-body inflammation that rises with age. It is now counted as one of the hallmarks of aging.
• Acetyl-CoA: the cell's only currency for attaching an "acetyl" tag to a protein. Here it is the raw material the cell needs to keep its inflammation genes open.
• Histone acetylation (H3K27ac): a chemical mark associated with active regulatory regions of DNA. It keeps the packaging around a gene loose enough for the cell's reading machinery to reach it. H3K27ac means the mark sits at lysine 27 of histone H3.
• SLC25A1: the transporter that carries citrate out of the mitochondria so the cell can turn it into acetyl-CoA. The valve on the fuel line.

The old plan was to kill the cell

Senescent cells earn their keep early in life. They stop damaged cells from dividing, which is one of the body's oldest defenses against cancer, and they help with wound healing and development. The problem is that they pile up with age and overstay their usefulness, sitting in tissue and leaking the SASP for years.³

The dominant response, pioneered in large part at Mayo, has been to clear them out. Drugs called senolytics selectively kill senescent cells, and in aged mice a senolytic combination improved physical function and even extended lifespan.⁴ That work is a genuine milestone, and it is tied to Mayo through the foundational contributions of James Kirkland and his colleagues. It put cellular senescence on the map as something you might actually treat.

This paper asks a different question. What if you do not have to kill the cell to stop the harm? What if you leave it in place, still holding its brakes on cell division, and just switch off the inflammation it is broadcasting? That is what the group set out to test, and the paper's own summary of the result is direct:

Why chronic inflammation matters as you age

Chronic inflammation is one of those phrases everyone uses and almost no one can define at the level of mechanism. It got formal status in 2023, when the field's most-cited map of aging added chronic inflammation to its list of hallmarks, the core processes that drive biological aging.² Inflammaging is the name for the version that matters here: not the sharp, useful inflammation of a cut or an infection, but a low, constant background hum that never resolves and slowly damages tissue.³

That hum is upstream of a lot of the diseases I usually write about. The inflamed immune cells that circulate in an aging body are part of why plaque turns unstable and why a heart attack can arrive with no warning, which is the ground I covered in the piece on clonal hematopoiesis. This post is one layer underneath that one. It is about one place age-related inflammation is manufactured in the first place.

The old story: the alarm

The first half of this story has been understood for a few years now. When a cell becomes senescent, its mitochondria, the small structures that produce most of its energy, start to malfunction. Damaged mitochondria leak their own DNA into the body of the cell, where it does not belong. The cell has an ancient alarm system, called cGAS-STING, that treats loose DNA as the signature of a virus and trips the inflammation response.¹ That was the accepted account of how a senescent cell starts to inflame: broken mitochondria set off an internal alarm.

The trouble is that the alarm alone did not fully explain the picture. Something else had to decide whether that alarm produced a loud, sustained inflammatory program or just a whisper. That missing piece is what this paper found.

The new story: the fuel line and the valve

The Mayo group showed that the same broken mitochondria do a second job. They run a metabolic assembly line, pyruvate to citrate to acetyl-CoA, and crank it up in senescent cells. Acetyl-CoA is the cell's raw material for a specific epigenetic tag, the acetyl mark on histones, and that tag is what keeps the DNA packaging around the inflammation genes loose enough to be read at full volume.¹ The mark they tracked sits at lysine 27 of histone H3, written H3K27ac.

The cleaner way to picture it is that the cell needs two separate inputs. Mitochondrial DNA sets off the alarm through cGAS-STING. Mitochondrial citrate metabolism supplies the acetyl-CoA that keeps the SASP genes accessible enough for that alarm to become a full transcriptional program. In the paper's own words these are "distinct but complementary pathways that converge to enable full SASP gene expression." Blocking either input lowers the SASP, and pushing on both produces a stronger response, which means there is no single master switch to find here. The alarm and the fuel line each do something the other one cannot.

That is the part worth zooming in on, because it is key. Inside one senescent cell, several hallmarks of aging are not just occurring side by side. Senescence changes mitochondrial signaling and metabolism. That metabolism changes what the epigenetic machinery can do. Open inflammation genes let the alarm be transcribed. And the SASP those genes produce is itself altered intercellular communication, the signal broadcast out of the cell and into the surrounding tissue, where it becomes chronic inflammation. Five hallmarks, one connected event, not five boxes to check off separately.

Then they did the cool part. They interrupted the assembly line at three points: pyruvate import through a carrier called MPC, citrate export through SLC25A1, and citrate conversion to acetyl-CoA through an enzyme called ACLY. The SASP fell at all three while the cell-cycle arrest stayed intact. At the SLC25A1 and ACLY steps, the acetyl tags on the inflammation genes fell too. And with the SLC25A1 blocker specifically, the cell's energy production, its mitochondrial respiration, and its overall shape were largely preserved. They were not reversing senescence or broadly poisoning the mitochondria. They were selectively turning down one output.

The cleanest lever was that middle valve, SLC25A1, and there is a tool compound that blocks it, called CTPI-2. That let them run the experiment that matters.

I am going to digress for a moment. A key point here is that this is all investigational at the most foundational level of biology. These are research compounds not intended to be taken by humans. As a word of caution, recall that my connection to studying aging biology came from my work in cancer. The two are inextricably interwoven. I say that to say this: while I am not against "biohacking" and people doing personal experiments, one reason I am not a huge fan of experimenting with research-grade peptides (the ones with zero or near-zero human data) and research compounds is that, not only is the legality questionable and in the gray, but these same compounds could pull a lever in the wrong way and cause cancer. I'm not saying that about the compound in this study, or about any peptide in particular, precisely because most don't have enough data for us to conclude one way or another. It is only a word of caution from a guy who spent years in a cancer lab seeing how complicated biology is, and how a treatment can be a near cure in one population and actually make things worse in another. Biology is complicated. Humans are complicated. What works in mice doesn't always translate, and may actually do the opposite in a human. Rant over.

What happened in the animals

They took aged mice, both male and female, and gave them CTPI-2 by mouth three times a week for three months, from 19 to 22 months of age, which is late life for a mouse. The treated animals were measurably less frail on a 31-parameter frailty index, had stronger grip, and grew larger muscle fibers.¹ All of this happened without wiping out the senescent cells.

I want to be careful about the tiers of evidence here, because they matter. This is mouse healthspan data plus human cells in a dish. There is no human trial. This was also healthspan, not lifespan: they measured frailty, strength, and tissue inflammation, not how long the animals lived.

And the effects were not uniform. Muscle function improved, but bone microarchitecture did not. In the heart, the treatment lowered both the secretory factors tied to the working heart-muscle cells and the classic SASP signals from the surrounding connective-tissue cells, and the drop in inflammatory immune-cell markers showed up more clearly in females. One lever, and the body did not respond as a single unit. Hold that thought, because it is the whole point of the last section.

The part that is personal for me

The tag at the center of this paper sits at lysine 27 of histone H3. That is the same histone position I was looking at years ago in cancer, from the other direction.

In the melanoma work I was part of, we found that as cells survived a targeted drug, they lost di- and trimethylation at that same lysine 27.⁷ Methylation and acetylation are two different chemical tags, and they are not interchangeable. On this spot they tend to do opposite jobs: those methyl marks are generally linked to silencing a gene, the acetyl mark to switching it on. We reported this as an association, part of the response of the surviving cells, not as proof that the single change caused the drug tolerance. In this Mayo paper, the acetyl mark at the very same residue appears to sustain inflammation in aging.

So the same tiny position on the same histone is a control point that cells write in more than one direction. I studied it changing one way as cancer cells escaped a drug. This group is studying it changing the other way as old cells learn to inflame. Cancer and aging are not separate biological worlds. They repeatedly corrupt the same regulatory machinery, sometimes in opposite directions and at very different speeds. That machinery has a name on the hallmarks map, epigenetic alteration, and it happens to be the corner of the map I know best. It is a large part of why I think aging is understood better through this kind of molecular detail than through any single disease label.

What I would actually do with this

This is where a good mechanism gets turned into bad marketing. Start with the supplement aisle. The market is full of products sold to "lower inflammation," and most of them target one node of a networked system. I spent fifteen years in the supplement industry, formulating and selling this exact category, so I will say it plainly: a single anti-inflammatory ingredient is a very small wrench thrown at a very large machine. That is a large part of why so many of these products look promising on a marker and then fail to move the outcomes that actually matter.

What does a lower CRP actually tell you?

CRP is the sharpest example. C-reactive protein is a blood marker of inflammation, and a lot of people, including plenty of clinicians, treat lowering it as if it were treating the underlying problem. It is not that simple. When researchers used genetics to test this directly, comparing people who inherit naturally higher or lower CRP for life, the lifelong difference in CRP did not translate into a difference in heart disease.⁵ That argues CRP is riding along with the fire rather than being the fire. I am not saying that a falling or rising CRP is meaningless. An intervention that changes an upstream pathway may lower CRP with it. But the number cannot tell you which source moved, whether the senescent-cell SASP was touched at all, or whether any hard outcome will improve. Marker movement is not mechanism, and mechanism is not outcome. This same logic will follow us into intervention analysis in the future. Just because a compound decreases CRP, it may not be working on the upstream mechanism at all, and this may just be noise, not true signal.

The CANTOS trial makes the distinction clean. Canakinumab, an antibody aimed at one specific inflammatory signal (interleukin-1β), lowered high-sensitivity CRP by 37 percentage points more than placebo at its 150-mg dose, and cut the primary cardiovascular event rate from 4.50 to 3.86 events per 100 person-years, a hazard ratio of 0.85.⁶ Real, but modest. And in the same trial, all-cause mortality did not improve, while fatal infections rose. A large drop in a marker, a genuine but small outcome benefit, and no net change in dying. That is what "targeting inflammation" actually looks like when it works: a precise, expensive biologic with real tradeoffs, not a scoop of powder, and a reminder that the marker and the outcome are different questions. It is also worth noting the contrast in incentives. CANTOS was funded by the drug's maker; the Mayo senescence paper was funded by public and non-profit sources with no competing interests declared.

You will hear a lot of discussion about conflicts of interest and economic incentives in my writing. As a guy who used to be in the boardroom before spending time at the scientific bench and the patient bedside, I believe conflict can be a true concern. However, conflict of interest and bias are not one and the same. Plenty of conflicted studies have zero bias and are very high quality, methodologically sound studies. Some, however, should have your eyebrow raised as high as Dwayne "The Rock" Johnson.

The Mayo paper does not get a free pass just because I like the mechanism. SLC25A1 and the citrate-to-acetyl-CoA line it feeds are not some isolated aging switch. That chemistry sits at the center of normal metabolism throughout the body. The mouse results are genuinely exciting, and they are also a live demonstration of the problem: one clean lever produced a scattered, tissue-specific, sex-specific set of effects, with bone left untouched. That is what tinkering with one component of a deeply connected system tends to look like. The upside is real and so is the unpredictability. Both are the message.

So when someone tells you a product or a protocol lowers inflammation, ask what actually changed: a marker, a mechanism, or an outcome. Those are three different claims, and most of what gets sold is the first one dressed up as the third.

The Final Signal

• What this paper gets right. It moves chronic inflammation from a vague phrase to a specific, testable mechanism, and it shows several hallmarks of aging working as one connected circuit: cellular senescence, mitochondrial dysfunction, epigenetic alteration, altered intercellular communication, and the inflammation they produce.
• What it cannot claim yet. Everything downstream of "improves healthspan" is in mice and cells. It measured healthspan, not lifespan; there is no human outcome data, and CTPI-2 is a laboratory research compound that no one can be prescribed.
• What it changes for me. It sharpens how I read the word inflammation. It is a system output, not a single dial, and I will keep asking of any "anti-inflammatory" claim whether it moved a marker, a mechanism, or an outcome.
• What would change my mind. A human trial showing that selectively quieting the SASP, without clearing the cells, improves a real outcome and not just a marker.
• What comes next. More of these foundational reads, hallmark by hallmark, and a companion primer on chronic inflammation over at Calibrated Age.

References

1. Martini H, Birch J, Marques FDM, et al. Mitochondrial metabolism and epigenetic crosstalk drive SASP. Nature. 2026. PMID: 42527602 · doi:10.1038/s41586-026-10791-2 [Finding: In senescent cells, mtDNA-cGAS-STING signaling and a mitochondrial citrate-to-acetyl-CoA pathway act as distinct but complementary inputs that together drive histone acetylation and full SASP expression; blocking the citrate exporter SLC25A1 reduced inflammation and improved healthspan in aged mice without clearing the cells.]
2. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. Cell. 2023;186(2):243-278. PMID: 36599349 [Finding: The updated hallmarks-of-aging framework that formally added chronic inflammation as a core hallmark.]
3. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69 Suppl 1:S4-9. PMID: 24833586 [Finding: Foundational review defining inflammaging as chronic, low-grade inflammation that rises with age and contributes to age-related disease.]
4. Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018;24(8):1246-1256. PMID: 29988130 [Finding: In aged mice, drugs that selectively kill senescent cells improved physical function and extended lifespan, establishing senolytics as a strategy.]
5. C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC). Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ. 2011;342:d548. PMID: 21325005 [Finding: Using inherited genetic differences in CRP, lifelong differences in CRP were not associated with coronary heart disease risk, arguing CRP is a marker rather than a cause.]
6. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-1131. PMID: 28845751 [Finding: Canakinumab (anti-IL-1β) lowered hs-CRP and cut the primary cardiovascular event rate (150-mg dose: 4.50 to 3.86 events per 100 person-years, HR 0.85), but did not reduce all-cause mortality and raised fatal infections.]
7. Grigore F, Yang H, Hanson ND, VanBrocklin MW, Sarver AL, Robinson JP. BRAF inhibition in melanoma is associated with the dysregulation of histone methylation and histone methyltransferases. Neoplasia. 2020;22(9):376-389. PMID: 32629178 [Finding: As melanoma cells survived BRAF-inhibitor therapy, histone methyltransferases were dysregulated and H3K9 and H3K27 di- and trimethylation were lost, changes the authors associated with the surviving drug-tolerant state.]